Fexofenadine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fexofenadine" in English language version.

refsWebsite

Global rank English rank

17nih.gov

4^th place

14doi.org

2^nd place

5web.archive.org

1^st place

3medicines.org.uk

3,823^rd place

2,387^th place

2drugs.com

399^th place

333^rd place

2semanticscholar.org

11^th place

8^th place

2clincalc.com

3,912^th place

2,496^th place

1sanofi.ca

low place

1books.google.com

3^rd place

1handle.net

102^nd place

76^th place

1drreddys.com

low place

1allegra.com

low place

1gov.uk

432^nd place

278^th place

allegra.com

"Allegra FAQs". Sanofi-Aventis. Archived from the original on 20 May 2011. Retrieved 5 July 2011.

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 548. ISBN 9783527607495.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Fexofenadine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, et al. (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". European Journal of Pharmaceutical Sciences. 40 (2): 125–131. doi:10.1016/j.ejps.2010.03.009. PMID 20307657.
Smith SM, Gums JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–822. doi:10.1517/17425250903044967. PMID 19545214. S2CID 19048690.
Bachert C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clinical Therapeutics. 31 (5): 921–944. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095.
Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, et al. (2011). "Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials". International Archives of Allergy and Immunology. 156 (1): 1–15. doi:10.1159/000321896. PMID 21969990.
Dicpinigaitis PV, Gayle YE (November 2003). "Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function". British Journal of Clinical Pharmacology. 56 (5): 501–504. doi:10.1046/j.1365-2125.2003.01902.x. PMC 1884387. PMID 14651723.
Welzel T, Ziesenitz VC, Seitz S, Donner B, van den Anker JN (November 2018). "Management of anaphylaxis and allergies in patients with long QT syndrome: A review of the current evidence". Annals of Allergy, Asthma & Immunology. 121 (5): 545–551. doi:10.1016/j.anai.2018.07.027. PMID 30059791.
Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G (October 2003). "Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis". Annals of Allergy, Asthma & Immunology. 91 (4): 354–361. doi:10.1016/S1081-1206(10)61682-1. PMID 14582814.
Grant JA, Riethuisen JM, Moulaert B, DeVos C (February 2002). "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects". Annals of Allergy, Asthma & Immunology. 88 (2): 190–197. doi:10.1016/S1081-1206(10)61995-3. PMID 11868924.
Casale TB, Andrade C, Qu R (1999). "Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis". Allergy and Asthma Proceedings. 20 (3): 193–198. doi:10.2500/108854199778553046. PMID 10389553.
Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J (November 1999). "Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis". The Journal of Allergy and Clinical Immunology. 104 (5): 927–933. doi:10.1016/s0091-6749(99)70070-9. PMID 10550734.
Philpot EE (January–February 2000). "Safety of second-generation antihistamines". Allergy and Asthma Proceedings. 21 (1): 15–20. doi:10.2500/108854100778249033. PMID 10748947.
Stoltz M, Arumugham T, Lippert C, Yu D, Bhargava V, Eller M, et al. (October 1997). "Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A)". Biopharmaceutics & Drug Disposition. 18 (7): 645–648. doi:10.1002/(SICI)1099-081X(199710)18:7<645::AID-BDD50>3.0.CO;2-3. PMID 9330784.
Shirasaka Y, Mori T, Murata Y, Nakanishi T, Tamai I (August 2014). "Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1". Pharmaceutical Research. 31 (8): 2035–2043. doi:10.1007/s11095-014-1305-7. PMID 24549825. S2CID 17532347.
Shehnaz H, Haider A, Arayne MS, Sultana N (November 2014). "Carboxyterfenadine antacid interaction monitoring by UV spectrophotometry and RP-HPLC techniques". Arabian Journal of Chemistry. 7 (5): 839–845. doi:10.1016/j.arabjc.2013.01.011.

drreddys.com

"Dr. Reddy's announces the launch of Over-the-Counter Fexofenadine HCl and Pseudoephedrine HCl extended-release tablets". Dr. Reddy's Laboratories Ltd. 30 August 2011. Archived from the original on 12 October 2016. Retrieved 27 May 2016.

drugs.com

"Fexofenadine Use During Pregnancy". Drugs.com. 1 April 2019. Retrieved 26 July 2020.
"Fexofenadine - international brand names". Drugs.com. Retrieved 18 January 2017.

gov.uk

"PAR: Reclassification of Allevia 120mg tablets from Prescription Only Medicine (POM) to General Sales List (GSL)". MHRA. 22 December 2020.

handle.net

hdl.handle.net

World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

medicines.org.uk

"Telfast 30mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 25 October 2019. Retrieved 20 June 2021.
"Almerg 180 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 20 June 2021.
"Fexofenadine Hydrochloride 120 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 22 March 2021. Archived from the original on 24 June 2021. Retrieved 20 June 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, et al. (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". European Journal of Pharmaceutical Sciences. 40 (2): 125–131. doi:10.1016/j.ejps.2010.03.009. PMID 20307657.
Smith SM, Gums JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–822. doi:10.1517/17425250903044967. PMID 19545214. S2CID 19048690.
Bachert C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clinical Therapeutics. 31 (5): 921–944. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095.
Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, et al. (2011). "Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials". International Archives of Allergy and Immunology. 156 (1): 1–15. doi:10.1159/000321896. PMID 21969990.
Dicpinigaitis PV, Gayle YE (November 2003). "Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function". British Journal of Clinical Pharmacology. 56 (5): 501–504. doi:10.1046/j.1365-2125.2003.01902.x. PMC 1884387. PMID 14651723.
Welzel T, Ziesenitz VC, Seitz S, Donner B, van den Anker JN (November 2018). "Management of anaphylaxis and allergies in patients with long QT syndrome: A review of the current evidence". Annals of Allergy, Asthma & Immunology. 121 (5): 545–551. doi:10.1016/j.anai.2018.07.027. PMID 30059791.
Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G (October 2003). "Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis". Annals of Allergy, Asthma & Immunology. 91 (4): 354–361. doi:10.1016/S1081-1206(10)61682-1. PMID 14582814.
Kruszewski J, Kłos K, Sułek K (November 2006). "[Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 i 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine--a randomized, double-blind, placebo controlled trial]". Polski Merkuriusz Lekarski. 21 (125): 443–448. PMID 17345837.
Grant JA, Riethuisen JM, Moulaert B, DeVos C (February 2002). "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects". Annals of Allergy, Asthma & Immunology. 88 (2): 190–197. doi:10.1016/S1081-1206(10)61995-3. PMID 11868924.
Casale TB, Andrade C, Qu R (1999). "Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis". Allergy and Asthma Proceedings. 20 (3): 193–198. doi:10.2500/108854199778553046. PMID 10389553.
Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J (November 1999). "Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis". The Journal of Allergy and Clinical Immunology. 104 (5): 927–933. doi:10.1016/s0091-6749(99)70070-9. PMID 10550734.
Philpot EE (January–February 2000). "Safety of second-generation antihistamines". Allergy and Asthma Proceedings. 21 (1): 15–20. doi:10.2500/108854100778249033. PMID 10748947.
Stoltz M, Arumugham T, Lippert C, Yu D, Bhargava V, Eller M, et al. (October 1997). "Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A)". Biopharmaceutics & Drug Disposition. 18 (7): 645–648. doi:10.1002/(SICI)1099-081X(199710)18:7<645::AID-BDD50>3.0.CO;2-3. PMID 9330784.
Shirasaka Y, Mori T, Murata Y, Nakanishi T, Tamai I (August 2014). "Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1". Pharmaceutical Research. 31 (8): 2035–2043. doi:10.1007/s11095-014-1305-7. PMID 24549825. S2CID 17532347.

dailymed.nlm.nih.gov

"Allegra (fexofenadine hydrochloride) tablet, orally disintegrating for oral use Allegra (fexofenadine hydrochloride) tablet, film coated for oral use Allegra (fexofenadine hydrochloride) suspension for oral useInitial U.S. Approval: 1996". DailyMed. 15 December 2008. Retrieved 13 February 2022.
"Allegra Allergy- fexofenadine hydrochloride tablet, coated". DailyMed. Retrieved 12 February 2022.

ncbi.nlm.nih.gov

Dicpinigaitis PV, Gayle YE (November 2003). "Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function". British Journal of Clinical Pharmacology. 56 (5): 501–504. doi:10.1046/j.1365-2125.2003.01902.x. PMC 1884387. PMID 14651723.

sanofi.ca

products.sanofi.ca

"ALLEGRA (fexofenadine hydrochloride) Product Monograph" (PDF). Sanofi Consumer Health Inc. 7 November 2019. Archived from the original (PDF) on 22 January 2021. Retrieved 2 November 2020.

semanticscholar.org

api.semanticscholar.org

Smith SM, Gums JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–822. doi:10.1517/17425250903044967. PMID 19545214. S2CID 19048690.
Shirasaka Y, Mori T, Murata Y, Nakanishi T, Tamai I (August 2014). "Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1". Pharmaceutical Research. 31 (8): 2035–2043. doi:10.1007/s11095-014-1305-7. PMID 24549825. S2CID 17532347.

web.archive.org

"Fexofenadine Hydrochloride 120 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 22 March 2021. Archived from the original on 24 June 2021. Retrieved 20 June 2021.
"ALLEGRA (fexofenadine hydrochloride) Product Monograph" (PDF). Sanofi Consumer Health Inc. 7 November 2019. Archived from the original (PDF) on 22 January 2021. Retrieved 2 November 2020.
"Dr. Reddy's announces the launch of Over-the-Counter Fexofenadine HCl and Pseudoephedrine HCl extended-release tablets". Dr. Reddy's Laboratories Ltd. 30 August 2011. Archived from the original on 12 October 2016. Retrieved 27 May 2016.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Allegra FAQs". Sanofi-Aventis. Archived from the original on 20 May 2011. Retrieved 5 July 2011.